From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2024 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“必须说服买家考虑”转变为“已获批准、指定、列入、合格、注册、报销或预先授权”的买家采购、报销、处方集、规格、采购、网络、目录或计划系统中的选择,从而使得未来业务中相当一部分可以无需每次单独销售即可到达,并且管理层是否传达了这种准入状态是新的,以至于其解锁的大部分业务量仍将在报告结果之后。 在记录中,管理层讨论了AI Explorer平台、GenAI参与、Oracle和SAP解决方案、全球S&BT细分市场等。没有提到公司被列入任何批准供应商名单、处方集、报销目录、采购计划或类似的具体买家侧系统。管理层谈论的是销售努力、客户参与、管道和增长,但没有描述公司被插入到常规交易流中的具体系统。没有提到“批准供应商”、“首选供应商”、“列入名单”、“合格”等术语。管理层提到“增值转售商活动”,但那是标准的转售协议,不是新的准入状态。管理层提到“AI Explorer”和“Hackett AI平台”,但那是产品,不是买家侧系统。管理层提到“市场情报计划”,但那是服务,不是准入状态。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.